NO20071798L - Dermalt pafore formuleringer for behandling av hudsykdommer i dyr - Google Patents

Dermalt pafore formuleringer for behandling av hudsykdommer i dyr

Info

Publication number
NO20071798L
NO20071798L NO20071798A NO20071798A NO20071798L NO 20071798 L NO20071798 L NO 20071798L NO 20071798 A NO20071798 A NO 20071798A NO 20071798 A NO20071798 A NO 20071798A NO 20071798 L NO20071798 L NO 20071798L
Authority
NO
Norway
Prior art keywords
animals
treatment
skin diseases
dermally
porous formulations
Prior art date
Application number
NO20071798A
Other languages
English (en)
Inventor
Kirkor Sirinyan
Holger Lehmann
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20071798L publication Critical patent/NO20071798L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

Det er beskrevet farmasøytiske formuleringer omfattende en trisykhsk forbindelse for dermal behandling av hudsykdommer i dyr.
NO20071798A 2004-09-16 2007-04-03 Dermalt pafore formuleringer for behandling av hudsykdommer i dyr NO20071798L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61049304P 2004-09-16 2004-09-16
PCT/EP2005/009468 WO2006029726A1 (en) 2004-09-16 2005-09-02 Dermally applicable formulations for treating skin diseases in animals

Publications (1)

Publication Number Publication Date
NO20071798L true NO20071798L (no) 2007-04-03

Family

ID=35229966

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071798A NO20071798L (no) 2004-09-16 2007-04-03 Dermalt pafore formuleringer for behandling av hudsykdommer i dyr

Country Status (9)

Country Link
US (1) US20080207670A1 (no)
EP (1) EP1791522A1 (no)
JP (1) JP2008513388A (no)
AU (1) AU2005284422A1 (no)
BR (1) BRPI0515378A (no)
CA (1) CA2580286A1 (no)
MX (1) MX2007002961A (no)
NO (1) NO20071798L (no)
WO (1) WO2006029726A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
NZ575118A (en) 2006-09-01 2012-04-27 Du Pont Local topical administration formulations containing indoxacarb and a crystallization inhibitor
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
TW200924647A (en) * 2007-08-30 2009-06-16 Schering Plough Ltd Local topical administration formulations containing fipronil
CA2825786A1 (en) * 2011-01-31 2012-08-09 Osaka University Externally-used drug for treating skin disorder and method for producing same
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
NZ630169A (en) * 2013-02-27 2017-07-28 Laurie Robert Batt Anhydrous transdermal formulations
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP4114357B1 (en) 2020-03-02 2025-10-01 Shanghai Aucta Pharmaceuticals Co., Ltd. Topical formulations containing mtor inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426333B1 (en) * 1996-09-19 2002-07-30 Merial Spot-on formulations for combating parasites
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
GB9205007D0 (en) * 1992-03-07 1992-04-22 Pfizer Ltd Antiparasitic agents
GB2327610B (en) * 1994-11-04 1999-06-02 Novartis Ag Macrolide compositions
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
GB9817064D0 (en) * 1998-08-05 1998-10-07 Fujisawa Pharmaceutical Co New use
GB0126253D0 (en) * 2001-10-31 2002-01-02 Metris Therapeutics Ltd Treatment method
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
BRPI0409185B1 (pt) * 2003-04-04 2018-05-15 Merial, Inc Formulações veterinárias anti-helmínticas tópicas

Also Published As

Publication number Publication date
AU2005284422A1 (en) 2006-03-23
JP2008513388A (ja) 2008-05-01
US20080207670A1 (en) 2008-08-28
CA2580286A1 (en) 2006-03-23
MX2007002961A (es) 2008-03-13
WO2006029726A1 (en) 2006-03-23
BRPI0515378A (pt) 2008-07-22
EP1791522A1 (en) 2007-06-06

Similar Documents

Publication Publication Date Title
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
BR0315023B1 (pt) distribuidor de composição anti-séptica de pele.
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
MX2007010996A (es) Nuevas composiciones de liposomas.
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
BRPI0408476A (pt) métodos para melhorar a qualidade da pele
DE502004008604D1 (de) Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
DK1819227T3 (da) Farmaceutisk formulering af decitabin
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
CY2018006I1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
WO2007030666A3 (en) Medicated skin care preparation for promoting wound healing
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application